The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. (Q48152092)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

title

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

24 March 2020

main subject

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Masahide Hamaguchi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yen-Hsuan Ni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Chun-Jen Liu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Seung Up Kim

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Khean-Lee Goh

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Shiv Chitturi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Wah-Kheong Chan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Grace Lai-Hung Wong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Simon Kin-Hung Wong

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Jose Sollano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yu-Cheng Lin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Laurentius Adrianto Lesmana

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Etsuko Hashimoto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Jiangao Fan

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Ajay Duseja

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yock Young Dan

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yogesh Chawla

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Geoff Farrell

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Henry Lik-Yuen Chan

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

publication date

1 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

24 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

86-98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

24 March 2020

cites work

1 reference

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

21 January 2018

1 reference

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

21 January 2018

1 reference

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

21 January 2018

1 reference

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

21 January 2018

1 reference

Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review.

21 January 2018

1 reference

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

21 January 2018

1 reference

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.

21 January 2018

1 reference

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study

21 January 2018

1 reference

American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise

21 January 2018

1 reference

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.

21 January 2018

1 reference

Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review

21 January 2018

1 reference

21 January 2018

1 reference

Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models

21 January 2018

1 reference

Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits

21 January 2018

1 reference

Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach

21 January 2018

1 reference

Pathogenesis and novel treatment options for non-alcoholic steatohepatitis

21 January 2018

1 reference

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.

21 January 2018

1 reference

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels

21 January 2018

1 reference

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

21 January 2018

1 reference

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

21 January 2018

1 reference

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis

21 January 2018

1 reference

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

21 January 2018

1 reference

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis

21 January 2018

1 reference

Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet

21 January 2018

1 reference

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

21 January 2018

1 reference

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

21 January 2018

1 reference

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

21 January 2018

1 reference

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis

21 January 2018

1 reference

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

21 January 2018

1 reference

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea

21 January 2018

1 reference

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

21 January 2018

1 reference

Effect of vildagliptin on hepatic steatosis

21 January 2018

1 reference

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

21 January 2018

1 reference

Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

Silymarin in non alcoholic fatty liver disease

21 January 2018

1 reference

Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study

21 January 2018

1 reference

The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes.

21 January 2018

1 reference

Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients

21 January 2018

1 reference

Statin safety: a systematic review

21 January 2018

1 reference

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

21 January 2018

1 reference

Nonalcoholic fatty liver disease and statins

21 January 2018

1 reference

An assessment by the Statin Liver Safety Task Force: 2014 update

21 January 2018

1 reference

Statin use in patients with cirrhosis: a retrospective cohort study

21 January 2018

1 reference

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

21 January 2018

1 reference

IFSO-APC consensus statements 2011.

21 January 2018

1 reference

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

21 January 2018

1 reference

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

21 January 2018

1 reference

The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome

21 January 2018

1 reference

The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis

21 January 2018

1 reference

Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?

21 January 2018

1 reference

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

21 January 2018

1 reference

The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012

21 January 2018

1 reference

How safe is metabolic/diabetes surgery?

21 January 2018

1 reference

A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis

21 January 2018

1 reference

Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery

21 January 2018

1 reference

Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery

21 January 2018

1 reference

Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery

21 January 2018

1 reference

Treating morbid obesity in cirrhosis: A quest of holy grail

21 January 2018

1 reference

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

21 January 2018

1 reference

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

21 January 2018

1 reference

Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management

21 January 2018

1 reference

Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.

21 January 2018

1 reference

Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease

21 January 2018

1 reference

Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom.

21 January 2018

1 reference

Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease

21 January 2018

1 reference

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

De novo nonalcoholic fatty liver disease after liver transplantation

21 January 2018

1 reference

Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation.

21 January 2018

1 reference

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials

21 January 2018

1 reference

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer

21 January 2018

1 reference

Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study

21 January 2018

1 reference

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

21 January 2018

1 reference

Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?

21 January 2018

1 reference

Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?

21 January 2018

1 reference

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease

21 January 2018

1 reference

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

21 January 2018

1 reference

Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan

21 January 2018

1 reference

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey

21 January 2018

1 reference

Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

21 January 2018

1 reference

Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.

21 January 2018

1 reference

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area

21 January 2018

1 reference

Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

21 January 2018

1 reference

Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice

21 January 2018

1 reference

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

21 January 2018

1 reference

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

21 January 2018

1 reference

Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease

21 January 2018

1 reference

Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.

21 January 2018

1 reference

In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores

21 January 2018

1 reference

Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

The interaction of metabolic factors with HCV infection: does it matter?

21 January 2018

1 reference

A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10).

21 January 2018

1 reference

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

21 January 2018

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?

21 January 2018

1 reference

Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

21 January 2018

1 reference

Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review

21 January 2018

1 reference

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action

21 January 2018

1 reference

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Review article: HCV genotype 3 – the new treatment challenge

21 January 2018

1 reference

Hepatitis B virus infection and metabolic syndrome: fact or fiction?

21 January 2018

1 reference

Hepatitis B virus infection and fatty liver in the general population

21 January 2018

1 reference

Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.

21 January 2018

1 reference

Hepatitis B virus seropositivity is not associated with increased risk of carotid atherosclerosis in Taiwanese

21 January 2018

1 reference

Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study

21 January 2018

1 reference

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations

21 January 2018

1 reference

Body-mass index and progression of hepatitis B: a population-based cohort study in men.

21 January 2018

1 reference

Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.

21 January 2018

1 reference

Chronic hepatitis B and fatty liver: Issues in clinical management.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.13856

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28692197%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference